Reported initial Phase 2 SURF302 results for oral dabogratinib in FGFR3-altered low-grade IR NMIBC patients Completed $400 million financing, providing additional capital to advance dabogratinib's 3x3 strategy Cash runway through 2030 with cash, cash equivalents and marketable securities of $700.5 million as of September 30, 2026 CARLSBAD, Calif., Nov. 10, 2026 /PRNewswire/ -- Tyra Biosciences,...
CARLSBAD, Calif., Sept. 14, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the pricing of an underwritten offering of 9,079,000 shares of its common stock at a price of $22.03 per share ...
- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) - - Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5th dose level, now expected end of Q1 2027 - - Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy - - Cash, cash equivalents and marketable securities of $353.9 million ...
-Collaboration aims to raise awareness of UTUC and the need for continued innovation for patients living with this rare and difficult-to-treat cancer- CARLSBAD, Calif., May 21, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Rec...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.